Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, Farrus B, Latre M L, Gimenez N, Hage M, Estape J, Ballesta A M
Department of Gynecology, Hospital Clinic, Medical School, Barcelona, Spain.
Anticancer Res. 1996 Jul-Aug;16(4B):2295-300.
C-erbB-2 serum levels were studied in the sera of 50 healthy subjects, 56 patients with benign breast diseases and 412 patients with breast cancer. Using 15 U/ml as the cut-off, no healthy subjects, patients with benign disease and only 2.4% of patients with no-evidence of disease had serum levels higher than this cut-off point. Abnormal c-erbB-2 levels were found in 9.2% of the patients with locoregional breast carcinoma and in 45.4% of those with advanced disease. C-erbB-2 serum levels in patients with locoregional breast cancer were not related to tumor size or nodal involvement. By contrast, significantly higher c-erbB-2 serum levels were found in ER- or PgR- tumors than in those ER+ or PgR+ tumors, in both locoregional or metastatic tumors. The correlation between serum and tissue levels of C-erbB-2 was studied in the tumors of 161 patients. Significantly higher c-erbB-2 serum levels were found in patients with overexpression in tissue by immunohistochemistry, in both locoregional and advanced disease (p = 0.0001). In patients with C-erbB-2 overexpression in tissue, c-erbB-2 serum levels were related to tumor size and nodes, with higher values in tumors greater than 5 cm or in those with more than 3 nodes involved. When the prognostic value of this oncoprotein was evaluated, patients with abnormally high presurgical c-erbB-2 had a worse prognosis than those patients with normal values, in both node-negative and node-positive patients. Serum concentrations in patients with advanced disease, were related to the site of recurrence with significantly higher values in patients with metastases (mainly in those with liver metastases) than in those with locoregional recurrence. In summary, c-erbB-2 serum level seem to be a useful tumor marker in the prognosis of patients with breast cancer.
对50名健康受试者、56名患有良性乳腺疾病的患者以及412名乳腺癌患者的血清进行了C-erbB-2血清水平研究。以15 U/ml作为临界值，没有健康受试者、良性疾病患者血清水平高于此临界值，只有2.4%无疾病证据的患者血清水平高于此临界值。9.2%的局部乳腺癌患者和45.4%的晚期疾病患者发现C-erbB-2水平异常。局部乳腺癌患者的C-erbB-2血清水平与肿瘤大小或淋巴结受累情况无关。相比之下，无论是局部肿瘤还是转移性肿瘤，ER-或PgR-肿瘤患者的C-erbB-2血清水平显著高于ER+或PgR+肿瘤患者。在161例患者的肿瘤中研究了C-erbB-2血清水平与组织水平之间的相关性。在局部和晚期疾病中，免疫组化显示组织中C-erbB-2过表达的患者血清C-erbB-2水平显著更高（p = 0.0001）。在组织中C-erbB-2过表达的患者中，C-erbB-2血清水平与肿瘤大小和淋巴结有关，肿瘤大于5 cm或有3个以上淋巴结受累的患者C-erbB-2血清水平更高。当评估这种癌蛋白的预后价值时，术前C-erbB-2异常高的患者预后比正常患者差，无论淋巴结阴性还是阳性患者均如此。晚期疾病患者的血清浓度与复发部位有关，转移患者（主要是肝转移患者）的血清浓度显著高于局部复发患者。总之，C-erbB-2血清水平似乎是乳腺癌患者预后的一个有用肿瘤标志物。
